These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30224292)

  • 1. Progress and pitfalls in measuring HIV preexposure prophylaxis coverage in the United States.
    Rosenberg ES; Marcus JL
    Ann Epidemiol; 2018 Dec; 28(12):830-832. PubMed ID: 30224292
    [No Abstract]   [Full Text] [Related]  

  • 2. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017.
    Sullivan PS; Giler RM; Mouhanna F; Pembleton ES; Guest JL; Jones J; Castel AD; Yeung H; Kramer M; McCallister S; Siegler AJ
    Ann Epidemiol; 2018 Dec; 28(12):833-840. PubMed ID: 30037634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States.
    Siegler AJ; Mouhanna F; Giler RM; Weiss K; Pembleton E; Guest J; Jones J; Castel A; Yeung H; Kramer M; McCallister S; Sullivan PS
    Ann Epidemiol; 2018 Dec; 28(12):841-849. PubMed ID: 29983236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Not Available].
    Nau JY
    Rev Med Suisse; 2016 Aug; 12(526):1346-1347. PubMed ID: 28671781
    [No Abstract]   [Full Text] [Related]  

  • 5. Murnane, Coley, and Baeten respond to "every good randomization deserves observation".
    Murnane PM; Coley RY; Baeten JM
    Am J Epidemiol; 2015 Nov; 182(10):861-2. PubMed ID: 26487341
    [No Abstract]   [Full Text] [Related]  

  • 6. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.
    Adams JL; Shelley K; Nicol MR
    Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV preexposure prophylaxis in Canadian primary care and community settings.
    Heendeniya A; Tumarkin E; Bogoch II
    Can Fam Physician; 2019 Apr; 65(4):271-272. PubMed ID: 30979761
    [No Abstract]   [Full Text] [Related]  

  • 8. ACP Journal Club. Preexposure tenofovir-emtricitabine reduced HIV infection in men who have unprotected anal sex with men.
    Sacks HS
    Ann Intern Med; 2016 Jan; 164(2):JC3. PubMed ID: 26784493
    [No Abstract]   [Full Text] [Related]  

  • 9. HOW DO I PAY FOR PrEP?
    Evans D
    Posit Aware; 2015; 27(5):18-9. PubMed ID: 26714339
    [No Abstract]   [Full Text] [Related]  

  • 10. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Mayer KH; Molina JM; Thompson MA; Anderson PL; Mounzer KC; De Wet JJ; DeJesus E; Jessen H; Grant RM; Ruane PJ; Wong P; Ebrahimi R; Zhong L; Mathias A; Callebaut C; Collins SE; Das M; McCallister S; Brainard DM; Brinson C; Clarke A; Coll P; Post FA; Hare CB
    Lancet; 2020 Jul; 396(10246):239-254. PubMed ID: 32711800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.
    Trang TP; Dong BJ; Kojima N; Klausner JD
    Expert Opin Drug Saf; 2016 Sep; 15(9):1287-94. PubMed ID: 27391203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic-Based Methods of Adherence Assessment in HIV Prevention.
    Brooks KM; Anderson PL
    Clin Pharmacol Ther; 2018 Dec; 104(6):1056-1059. PubMed ID: 30178462
    [No Abstract]   [Full Text] [Related]  

  • 13. Feasibility of HIV Pre-Exposure Prophylaxis as Part of Routine Care in Toronto, Canada.
    Rajchgot J; Siemieniuk RA; Sivachandran N; Murphy P; Sharp A; Cicci A; Bogoch II
    J Acquir Immune Defic Syndr; 2016 Jul; 72(3):e80-1. PubMed ID: 27035886
    [No Abstract]   [Full Text] [Related]  

  • 14. MOVING FORWARD WITH PrEP. THE BASICS OF PrEP.
    Highleyman L
    Posit Aware; 2015; 27(5):2-3. PubMed ID: 26714333
    [No Abstract]   [Full Text] [Related]  

  • 15. HIV preexposure prophylaxis for adolescents and young adults.
    Allen E; Gordon A; Krakower D; Hsu K
    Curr Opin Pediatr; 2017 Aug; 29(4):399-406. PubMed ID: 28598901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV moments and pre-exposure prophylaxis.
    Grant RM; Glidden DV
    Lancet; 2016 Apr; 387(10027):1507-1508. PubMed ID: 27115970
    [No Abstract]   [Full Text] [Related]  

  • 17. Truvada (emtricitabine/tenofovir) pre-exposure prophylaxis roll-out among South African university students: Lots of positives, but let us keep an eye on possible surprises.
    Montjane K; Dlamini S; Dandara C
    S Afr Med J; 2018 Feb; 108(2):79-81. PubMed ID: 29429434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV moments and pre-exposure prophylaxis--Authors' reply.
    Dunn DT; Gafos M; White E; McCormack S
    Lancet; 2016 Apr; 387(10027):1508. PubMed ID: 27115971
    [No Abstract]   [Full Text] [Related]  

  • 19. [HIV pre-exposure prophylaxis does not increase the rate of STI].
    Blondel N
    Rev Med Suisse; 2016 Jan; 12(503):236. PubMed ID: 26939198
    [No Abstract]   [Full Text] [Related]  

  • 20. Intentions to prescribe preexposure prophylaxis are associated with self-efficacy and normative beliefs.
    Sachdev DD; Stojanovski K; Liu AY; Buchbinder SP; Macalino GE
    Clin Infect Dis; 2014 Jun; 58(12):1786-7. PubMed ID: 24729556
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.